Kinetolab

team of
professionals:
this is KIneto lab

Our mission is to enhance the quality of drug discovery and developmental concept of our partners using scientifically founded strategies and provide high quality services, in order to reach the clinical stage faster and with higher reliability

info@kinetolab.hu
+36 20 914 6882

1037 Budapest, Hungary
Csillaghegyi út 19-21.

we are committed to

innovation and excellence

we manage

the whole process of drug development from target identification and validation through high throughput in vitro screenings to in vivo animal model studies

we grow
our biobank of PDTX models to provide a more sophisticated platform to our partners, offering clinically relevant models, improving the reliability of translational research
we develop

wide range of preclinical models, originated from human (xenograft) or murine (allo-/iso-graft) tumor cell lines, for testing various anticancer strategies and treatments

History

15 years of experience in cancer research.

KINETO Lab is a privately owned biotechnology research and CRO company based in Budapest, Hungary.

15 years of experience in cancer research.

KINETO Lab is a privately owned biotechnology research and CRO company based in Budapest, Hungary.

company Establishment

Two of founders, Attila Kigyós and József Tóvári are the owners and are working for the company

20
07

“Magicbullet” consortium

KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet” consortium

read more

20
15

endothelial markers

Tumor endothelial cell
research launched

read more

20
17

PDTX biobank

First PDTX models established, PDTX biobank launched

read more

20
19

NEW KRAS CONSORTIUM

The Company joined the Hungarian new KRAS consortium

read more

20
21

BIOSMALL CONSORTIUM

KINETO Lab Ltd. participating in Horizon
2020 Marie Skłodowska-Curie
“BIOSMALL” consortium

read more

20
23

20
10

CD34 antibody

First own CD34 antibody developed

read more

20
16

KRAS consortium

The Company joined the Hungarian KRAS consortium (RASopathies)

read more

20
18

“Magicbullet::Reloaded”

KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet::Reloaded” consortium

read more

20
20

related PhD work

Our work on endothelial cells reinforced by the company’s first related PhD research

read more

20
22

NEXGEN CONSORTIUM

KINETO Lab Ltd. participating in HORIZON-HLTH to develop the Next generation vaccine platform for the treatment of Parkinson’s disease

read more

company Establishment

Two of founders, Attila Kigyós and József Tóvári are the owners and are working for the company

20
07

CD34 antibody

First own CD34 antibody developed

read more

20
10

“Magicbullet” consortium

KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet” consortium

read more

20
15

KRAS consortium

The Company joined the Hungarian KRAS consortium (RASopathies)

read more

20
16

endothelial markers

Tumor endothelial cell
research launched

read more

20
17

“Magicbullet: :Reloaded”

KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet::Reloaded” consortium

read more

20
18

PDTX biobank

First PDTX models established, PDTX biobank launched

read more

20
19

related PhD work

Our work on endothelial cells reinforced by the company’s first related PhD research

read more

20
20

NEW KRAS CONSORTIUM

The Company joined the Hungarian new KRAS consortium

read more

20
21

NEXGEN CONSORTIUM

KINETO Lab Ltd. participating in HORIZON-HLTH to develop the Next generation vaccine platform for the treatment of Parkinson’s disease

read more

20
22

BIOSMALL CONSORTIUM

KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie “BIOSMALL” consortium

read more

20
23

MANAGEMENT

Acknowledged experts providing tailored approaches for successful and effective research and development. Giving in our hands your concept guarantee you high quality investigation.

Attila Kigyós

founder and CEO KINETO Lab

«Drug development today requires effective collaboration between different disciplines. I consider it very important that our company excels in coordinating the work of chemists, biologists and statisticians. Therefore, I can confidently recommend our services to chemical researchers developing drugs, not only in the testing of their drug candidates, but also in the planning phase of the project.»

trust.
efficiency.
knowledge.

Attila Kigyós

MSc, Chief Executive Officer

József Tóvári

PhD, Chief Scientific Officer

Mihály Cserepes

PhD, Project Manager

Ivan Ranđelović

PhD, Project Manager

Attila Kigyós

MSc, Chief Executive Officer

Attila Kigyós, MSc, is the founder and CEO of KINETO Lab Research and Development Ltd. In addition to his role as Managing Director of the company, Attila has more than two decades of experience in the fields of informatics, biotechnology and drug discovery screening.

Attila was appointed for CEO based on his leadership experience in managing Hungarian biotech companies and his strong leadership and personal qualities.

read more

He graduated in chemistry at Eötvös Loránd University in Budapest in 1992. After graduation, he worked for four years as a teaching assistant and demonstrator at the Budapest University of Technology and Economics.

In 1993, he spent a year as a researcher at the Eindhoven University of Technology in the Netherlands, where he attended intensive complementary courses to further develop his knowledge.

In 1998, he founded his first company in Hungary, where he was and still is managing director. In the meantime, he has been involved in the establishment of several companies and is now managing director of two of them. The companies he founded and managed are working in the IT and biotechnology industries.

József Tóvári

PhD, Chief Scientific Officer

József Tóvári, PhD, is the founder and CSO of KINETO Lab Research and Development Ltd., head of the Department of Experimental Pharmacology, National Institute of Oncology, Budapest.

Dr. Tóvari has a strong scientific experience in the field of translational applied research and development in oncology. He is co-author of 120 scientific publications; his cumulative impact factor is >500. He has >2800 independent citations.

read more

After graduating as a biologist at the Eötvös Loránd University, Budapest in 1994, he continued his former research activities at the 1st Institute of Pathology and Experimental Cancer Research of the Semmelweis University of Medicine, Budapest. His main field of interest was the investigation of tumor metastasis including cell migration, invasion and interaction with extracellular matrices.

From the finishing of his PhD thesis in 1999 (title: Regulation of tumor cell – extracellular-matrix interaction in tumor metastasis process) he is working in the so called Metastasis Research Group in the National Institute of Oncology, Budapest and the National Korányi Institute of TB and Pulmonology, Budapest.

He was visiting scientist in Finland (University of Turku) and Switzerland (ETH) several times for various time periods with the help of joint research grants. He is member of three scientific associations (AACR, EACR, MOT) and supervises research works of ten PhD and several undergraduate students from the faculty of natural science or medicine. His scientific work was awarded with Young Scientist Award (2000), György Miklós Award (2005) and Bolyai Scholarship (2001-2004) of the Hungarian Academy of Sciences, EJC-Pharmamar Grant for young scientist (2004) and AACR-NCI International Investigator Opportunity Grants (2008). Dr. Tóvári holds lectures on cell motility, tumor angiogenesis, drug development and biotechnology at Semmelweis University and Eötvös Loránd University, Budapest, Hungary.

Mihály Cserepes

PhD, Project Manager

Mihály is a postdoctoral biologist researcher and project manager in KINETO Lab, focusing his work on Patient-derived xenograft models, primary tumor cell line establishment and antibody development, as well as in vivo experiment planning and supervision.

Mihály is author of 13 peer-reviewed articles, with the total impact factor of 82.2, and 247 citations (as of February, 2023). He attended to more than 15 scientific conferences, earning two prizes for best poster.

read more

Mihály earned his MSc diploma in 2006 at Eötvös Loránd University, Budapest. After gaining practice in different cancer biology lab techniques in the National Korányi Institute of Pulmonology, he attended the Doctoral School of Pathological Sciences at Semmelweis University, under the supervision of József Tóvári (National Institute of Oncology) and Gergely Szakács (ELKH-TTK, Institute of enzymology). He defended his PhD thesis in 2020.

Currently, he is also supervisor of a PhD student at the Department of Experimental Pharmacology of the National Institute of Oncology as a postdoctoral research fellow. His main area of interest involves tumor heterogeneity, patient-derived xenograft models, tumor hypoxia & metabolism, and chemotherapy resistance in cancer. He is the principal investigator of a postdoctoral OTKA research grant (2022-2025) from National Research, Development and Innovation Office, relating acquired drug resistance in PDTX models.

Ivan Ranđelović

PhD, Project Manager

Ivan Ranđelović, PhD, is postdoctoral biologist researcher and project manager in KINETO Lab, focusing on drug discovery and preclinical investigation and development of targeting cancer therapeutics. Ivan is also responsible for the marketing and international relations of the company.

Ivan is author of 16 articles published in international peer-reviewed journals with a total impact factor of 64.1 which independently were cited over 100 times. He represented his work on numerous scientific conferences, where earned one prize for the best poster.

read more

Ivan graduated at Belgrade University, Belgrade, Serbia, on Faculty of Biology, on Department for Molecular Biology and Physiology, module of Experimental Biomedicine in 2014. In his Master thesis he investigated anticancer activity and mechanism of actions of Iridium (III) complexes with various ligands.

From 2015. as Marie Skłodowska-Curie PhD fellow he works on National Institute of Oncology, Budapest, Hungary, at the Department of Experimental Pharmacology, under supervision of József Tóvári, PhD, investigating the effect of small molecule and peptide-drug conjugates for targeted drug delivery on tumor growth and metastasis in vitro and in vivo, in the frame of Innovative and European Training Network “MAGICBULLET”.

In 2017. he was on secondment in Translational Cancer Biology lab on Biomedicum at Helsinki University, Finland, and in 2018. in Molecular Biology lab at the Research Center of Italfarmaco SpA, Milan, Italy.

In 2021. Ivan defended his PhD thesis on Semmelweis University, Budapest, Hungary, at the Doctoral School of Pathological Sciences, on Experimental Oncology program.

trust.
efficiency.
knowledge.

Attila Kigyós

Chief Executive Officer

Attila Kigyós, MSc, is the founder and CEO of KINETO Lab Research and Development Ltd. In addition to his role as Managing Director of the company, Attila has more than two decades of experience in the fields of informatics, biotechnology and drug discovery screening.

Attila was appointed for CEO based on his leadership experience in managing Hungarian biotech companies and his strong leadership and personal qualities.

read more

He graduated in chemistry at Eötvös Loránd University in Budapest in 1992. After graduation, he worked for four years as a teaching assistant and demonstrator at the Budapest University of Technology and Economics.

In 1993, he spent a year as a researcher at the Eindhoven University of Technology in the Netherlands, where he attended intensive complementary courses to further develop his knowledge.

In 1998, he founded his first company in Hungary, where he was and still is managing director. In the meantime, he has been involved in the establishment of several companies and is now managing director of two of them. The companies he founded and managed are working in the IT and biotechnology industries.

József Tóvári

Chief Scientific Officer

József Tóvári, PhD, is the founder and CSO of KINETO Lab Research and Development Ltd., head of the Department of Experimental Pharmacology, National Institute of Oncology, Budapest.
Dr. Tóvari has a strong scientific experience in the field of translational applied research and development in oncology. He is co-author of 120 scientific publications; his cumulative impact factor is >500. He has >2800 independent citations.

read more

After graduating as a biologist at the Eötvös Loránd University, Budapest in 1994, he continued his former research activities at the 1st Institute of Pathology and Experimental Cancer Research of the Semmelweis University of Medicine, Budapest. His main field of interest was the investigation of tumor metastasis including cell migration, invasion and interaction with extracellular matrices.

From the finishing of his PhD thesis in 1999 (title: Regulation of tumor cell – extracellular-matrix interaction in tumor metastasis process) he is working in the so called Metastasis Research Group in the National Institute of Oncology, Budapest and the National Korányi Institute of TB and Pulmonology, Budapest.

He was visiting scientist in Finland (University of Turku) and Switzerland (ETH) several times for various time periods with the help of joint research grants. He is member of three scientific associations (AACR, EACR, MOT) and supervises research works of ten PhD and several undergraduate students from the faculty of natural science or medicine. His scientific work was awarded with Young Scientist Award (2000), György Miklós Award (2005) and Bolyai Scholarship (2001-2004) of the Hungarian Academy of Sciences, EJC-Pharmamar Grant for young scientist (2004) and AACR-NCI International Investigator Opportunity Grants (2008). Dr. Tóvári holds lectures on cell motility, tumor angiogenesis, drug development and biotechnology at Semmelweis University and Eötvös Loránd University, Budapest, Hungary.

Mihály Cserepes

PhD, Project Manager

Mihály is a postdoctoral biologist researcher and project manager in KINETO Lab, focusing his work on Patient-derived xenograft models, primary tumor cell line establishment and antibody development, as well as in vivo experiment planning and supervision.

Mihály is author of 13 peer-reviewed articles, with the total impact factor of 82.2, and 247 citations (as of February, 2023). He attended to more than 15 scientific conferences, earning two prizes for best poster.

read more

Mihály earned his MSc diploma in 2006 at Eötvös Loránd University, Budapest. After gaining practice in different cancer biology lab techniques in the National Korányi Institute of Pulmonology, he attended the Doctoral School of Pathological Sciences at Semmelweis University, under the supervision of József Tóvári (National Institute of Oncology) and Gergely Szakács (ELKH-TTK, Institute of enzymology). He defended his PhD thesis in 2020.

Currently, he is also supervisor of a PhD student at the Department of Experimental Pharmacology of the National Institute of Oncology as a postdoctoral research fellow. His main area of interest involves tumor heterogeneity, patient-derived xenograft models, tumor hypoxia & metabolism, and chemotherapy resistance in cancer. He is the principal investigator of a postdoctoral OTKA research grant (2022-2025) from National Research, Development and Innovation Office, relating acquired drug resistance in PDTX models.

Ivan Ranđelović

PhD, Project Manager

Ivan Ranđelović, PhD, is postdoctoral biologist researcher and project manager in KINETO Lab, focusing on drug discovery and preclinical investigation and development of targeting cancer therapeutics. Ivan is also responsible for the marketing and international relations of the company.

Ivan is author of 16 articles published in international peer-reviewed journals with a total impact factor of 64.1 which independently were cited over 100 times. He represented his work on numerous scientific conferences, where earned one prize for the best poster.

read more

Ivan graduated at Belgrade University, Belgrade, Serbia, on Faculty of Biology, on Department for Molecular Biology and Physiology, module of Experimental Biomedicine in 2014. In his Master thesis he investigated anticancer activity and mechanism of actions of Iridium (III) complexes with various ligands.

From 2015. as Marie Skłodowska-Curie PhD fellow he works on National Institute of Oncology, Budapest, Hungary, at the Department of Experimental Pharmacology, under supervision of József Tóvári, PhD, investigating the effect of small molecule and peptide-drug conjugates for targeted drug delivery on tumor growth and metastasis in vitro and in vivo, in the frame of Innovative and European Training Network “MAGICBULLET”.

In 2017. he was on secondment in Translational Cancer Biology lab on Biomedicum at Helsinki University, Finland, and in 2018. in Molecular Biology lab at the Research Center of Italfarmaco SpA, Milan, Italy.

In 2021. Ivan defended his PhD thesis on Semmelweis University, Budapest, Hungary, at the Doctoral School of Pathological Sciences, on Experimental Oncology program.

Team

Acknowledged experts providing tailored approaches for successful and effective research and development. Giving in our hands your concept guarantee you high quality investigation.

trust.
efficiency.
knowledge.

Marcell Baranyi

PhD, Project Manager

Sára Eszter Surguta

MSc, Biologist Researcher

Laura Svajda

MSc, Biologist Researcher

Marcell Baranyi

PhD, Project Manager

Marcell is a postdoctoral research member and project manager in KINETO Lab. Marcell’s expertise covers various in vitro cellular and molecular techniques, focusing on 3D cellular models and the development of new methodologies.

read more

Marcell graduated at Eötvös Loránd University, Budapest in 2017. He started his early research career at 2nd Department of Pathology, Semmelweis University as a PhD student under the supervision of prof. dr. József Tímár. He earned his PhD degree in 2022. During his PhD studies, he participated in two major Hungarian grant projects focusing on KRAS targeting and won three times scholarships for excellence provided by the Hungarian National Research, Development and Innovation Office.

Marcell is the author of 12 peer-reviewed articles, has a cumulative impact factor above 60 and was cited independently more than 100 times.

Sára Eszter Surguta

MSc, Biologist Researcher

Sára is a biologist researcher and project manager at KINETO Lab. Her expertise lies in meticulously planning and overseeing in vivo experiments, alongside conducting in vitro work and research in the fields of cell and molecular biology.

read more

She earned her master’s degree in Cell and Molecular Biology from Szeged University in 2020, where her academic journey was enriched by a six-month period in Paris at the EPHE (École Pratique des Hautes Études). During her time there, she contributed as an intern at the CRI (Centre de Recherches Interdisciplinaires) Institute.

Continuing her academic career, Sára began her PhD at Semmelweis University, specializing in the Department of Pathology and Oncology. Her dedication and passion for research were acknowledged when in collaboration with KINETO Lab. Ltd, she secured a KDP scholarship (2020-2024) awarded by the Ministry of Culture and Innovation of Hungary.

This cooperative doctoral program focuses on harnessing the transformative potential of Sára’s doctoral research outcomes for industrial application within KINETO Lab. It aims to bridge the gap between fundamental research and practical industrial utilization, paving the way for groundbreaking advancements in the field.

Laura Svajda

MSc, Biologist Researcher

Laura is instrumental in product development and designing and performing in vivo experiments on murine models in KINETO Lab Ltd. With an analytical mind and a dedication to scholarly excellence, coupled with her hands-on experience in industry, she is uniquely positioned to integrate practical insights into her research, driving innovation and advancing scientific knowledge.

read more

Laura has established a robust academic background, culminating in a Master of Science degree in Pharmaceutical Sciences from the University of Copenhagen, complemented by ongoing doctoral research in oncology at Semmelweis University.

With a Bachelor of Science in Biomedical Engineering as her foundation, she pursued advanced studies, earning a Master of Science in the same field, demonstrating a commitment to interdisciplinary learning and expertise. This educational journey has equipped her with a comprehensive understanding of biochemical processes and pharmaceutical principles, enabling her to effectively combat scientific challenges.

Furthermore, her experience across different fields, including quality control, laboratory research, and pharmaceutical development, has provided her with a unique advantage in problem-solving and strategic thinking.

trust.
efficiency.
knowledge.

Marcell Baranyi

PhD, Project Manager

Marcell is a postdoctoral research member and project manager in KINETO Lab. Marcell’s expertise covers various in vitro cellular and molecular techniques, focusing on 3D cellular models and the development of new methodologies.

read more

Marcell graduated at Eötvös Loránd University, Budapest in 2017. He started his early research career at 2nd Department of Pathology, Semmelweis University as a PhD student under the supervision of prof. dr. József Tímár. He earned his PhD degree in 2022. During his PhD studies, he participated in two major Hungarian grant projects focusing on KRAS targeting and won three times scholarships for excellence provided by the Hungarian National Research, Development and Innovation Office.

Marcell is the author of 12 peer-reviewed articles, has a cumulative impact factor above 60 and was cited independently more than 100 times.

Sára Eszter Surguta

MSc, Biologist Researcher

Sára is a biologist researcher and project manager at KINETO Lab. Her expertise lies in meticulously planning and overseeing in vivo experiments, alongside conducting in vitro work and research in the fields of cell and molecular biology.

read more

She earned her master’s degree in Cell and Molecular Biology from Szeged University in 2020, where her academic journey was enriched by a six-month period in Paris at the EPHE (École Pratique des Hautes Études). During her time there, she contributed as an intern at the CRI (Centre de Recherches Interdisciplinaires) Institute.

Continuing her academic career, Sára began her PhD at Semmelweis University, specializing in the Department of Pathology and Oncology. Her dedication and passion for research were acknowledged when in collaboration with KINETO Lab. Ltd, she secured a KDP scholarship (2020-2024) awarded by the Ministry of Culture and Innovation of Hungary.

This cooperative doctoral program focuses on harnessing the transformative potential of Sára’s doctoral research outcomes for industrial application within KINETO Lab. It aims to bridge the gap between fundamental research and practical industrial utilization, paving the way for groundbreaking advancements in the field.

Laura Svajda

MSc, Biologist Researcher

Laura is instrumental in product development and designing and performing in vivo experiments on murine models in KINETO Lab Ltd. With an analytical mind and a dedication to scholarly excellence, coupled with her hands-on experience in industry, she is uniquely positioned to integrate practical insights into her research, driving innovation and advancing scientific knowledge.

read more

Laura has established a robust academic background, culminating in a Master of Science degree in Pharmaceutical Sciences from the University of Copenhagen, complemented by ongoing doctoral research in oncology at Semmelweis University.

With a Bachelor of Science in Biomedical Engineering as her foundation, she pursued advanced studies, earning a Master of Science in the same field, demonstrating a commitment to interdisciplinary learning and expertise. This educational journey has equipped her with a comprehensive understanding of biochemical processes and pharmaceutical principles, enabling her to effectively combat scientific challenges.

Furthermore, her experience across different fields, including quality control, laboratory research, and pharmaceutical development, has provided her with a unique advantage in problem-solving and strategic thinking.

publications

all publications

PEPTIDE-DRUG CONJUGATES

Optimizing the Enzymatic Release of MMAE from isoDGR-based Small Molecule Drug Conjugate by Incorporation of a GPLG-PABC Enzymatically Cleavable Linker.
Zambra M, Ranđelović I, Talarico F, Borbély A, Svajda L, Tóvári J, Mező G, Bodero L, Colombo S, Arrigoni F, Fasola E, Gazzola S, Piarulli U.
Front Pharmacol. 2023, 14:1215694.

PDTX

Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets.
Tóvári J, Vári-Mező D, Surguta SE, Ladányi A, Kigyós A, Cserepes M.
Cells. 2023, 12(14), 1919.

KRAS TARGETING – with FARNESYL-TRANSFERASE inhibitors

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
Baranyi M, Molnár E, Hegedűs L, Gábriel Z, Petényi FG, Bordás F, Léner L, Ranđelović I, Cserepes M, Tóvári J, Hegedűs B, Tímár J.
Br J Cancer. 2024.

we Develop PDTX models resembling tumor heterogeneity and tumor microenvironment for better predictability of clinical therapeutic response

FACILITIES

We have licensed laboratory fully equipped with instruments for in vitro cell-based analysis and for molecular biology techniques, histochemical and patological studies. As well there is animal house for conducting animal experiments, with all official and ethical approvals.

technology

for histochemical & pathological studies

SPF

animal house

IVIS

in vivo imaging system

EQUIPPED

for cell culturing & molecular biology studies

R1_L0426-Edit.jpeg
R1_L1030-Edit.jpeg
R1_L1118.jpeg
R1_L0813-Edit.jpeg
R1_L0626-Edit.jpeg
R1_L0605-Edit.jpeg
R1_L0579.jpeg
R1_L0452-Edit-2.jpeg
R1_L0524-Edit.jpeg
R1_L0426-Edit.jpeg
R1_L1030-Edit.jpeg
R1_L1118.jpeg
R1_L0813-Edit.jpeg
R1_L0626-Edit.jpeg
R1_L0605-Edit.jpeg
R1_L0579.jpeg
R1_L0452-Edit-2.jpeg
R1_L0524-Edit.jpeg

NEWS​

read all news

07/03/2024

Published a study about a gluing docking method for finding small molecules that bind to both the GAP and the mutated KRAS molecules

read more

10/02/2024

Published a new study on targeting KRAS with combination of KRAS-G12C and Farnesyl-transferase inhibitors in British Journal of Cancer

read more

05/01/2024

Attending NEXGEN-PD consortium meeting on January 11th to 12th, 2024 in Salzburg, Austria

read more

CONTACTS

If you have any question regarding our research, services or PDTX models, and if you want to get in touch with us, fill the form or send us an e-mail on info@kinetolab.hu.

We are always open for your CV and application in case you would like to work in an innovative, dynamically growing cancer research-related biotech company in the future. If you think you could fit in KINETO Lab’s team, please contact us.